Impact of sodium glucose cotransporter 2 inhibitors on bladder cancer and breast cancer: a pharmacovigilance analysis and Mendelian randomization study
Our results suggest that the use of SGLT2 inhibitors is associated with a higher reporting frequency/risk of bladder cancer, rather than breast cancer.
Authors
- Aihua Jiang
- Bo Xu (ORCID: https://orcid.org/0000-0003-0594-9103)
- Yinglan Liu
- Yun He (ORCID: https://orcid.org/0000-0001-7263-3243)
- Jiecan Zhou (ORCID: https://orcid.org/0000-0002-3037-3997)
- Zunbo He
- Tianqiao Zhang (ORCID: https://orcid.org/0009-0003-4923-5142)
Institutions
- Sun Yat-sen University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- First Affiliated Hospital of University of South China (CN)
- South China University of Technology (CN)
- University of South China (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1080/14740338.2025.2595727
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00